Tag: hypertrophic cardiomyopathy
Edgewise Therapeutics initiates EDG-7500 Phase 1 trial targeting cardiac diseases
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a biopharmaceutical company specializing in muscle diseases, announced the commencement of its Phase 1 trial for EDG-7500. This oral, selective, ... Read More
Viz.ai, Bristol Myers Squibb sign deal for AI algorithm and Viz HCM software
Viz.ai, an artificial intelligence (AI) powered health technology company, has signed a multi-year agreement with Bristol Myers Squibb (BMY) to provide the latter with an ... Read More
Cytokinetics bags FDA breakthrough therapy status for aficamten in oHCM
Cytokinetics has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). ... Read More